Skip to content
Signet Laboratories

Signet Laboratories

Antibodies, antigens, purifies IgG fractions purified biotinylated

Menu
  • Home
  • primers
  • probe
  • E coli
  • Preps
  • Distributors
  • Contact Us
Menu
HLA-B and cysteinylated ligands distinguish the antigen presentation landscape of extracellular vesicles

HLA-B and cysteinylated ligands distinguish the antigen presentation landscape of extracellular vesicles

Posted on July 23, 2021July 23, 2021 by Faith

Extracellular vesicles can modulate numerous processes starting from proliferation and tissue restore, to chemo-resistance and mobile differentiation. With the introduction of tissue and immunological focusing on, extracellular vesicles are additionally more and more seen as promising vectors to ship peptide-based most cancers antigens to the human immune system.

Despite the medical relevance and therapeutic potential of such ‘cell-free’ approaches, the pure antigen presentation landscape exported in extracellular vesicles remains to be largely uncharted, as a result of the difficult nature of such preparations and analyses. In the context of therapeutic vesicle manufacturing, a essential analysis of the similarity in vesicular antigen presentation can also be urgently wanted. In this work, we in contrast the HLA-I peptide ligandomes of extracellular vesicles towards that of whole-cells of the similar cell line.

We discovered that extracellular vesicles not solely over-represent HLA-B complexes and peptide ligands, but additionally cysteinylated peptides that will modulate immune responses. Collectively, these findings describe the pre-existing provision of vesicular HLA complexes which may be utilized to hold peptide vaccines, in addition to the propensity for various peptide and post-translationally modified ligands to be introduced, and will define essential concerns in devising novel EV vaccination methods.

Bioorthogonal protein labelling allows the examine of antigen processing of citrullinated and carbamylated auto-antigens

Proteolysis is key to many organic processes. In the immune system, it underpins the activation of the adaptive immune response: degradation of antigenic materials into quick peptides and presentation thereof on main histocompatibility complexes, results in activation of T-cells. This initiates the adaptive immune response towards many pathogens.

Studying proteolysis is tough, as the oft-used polypeptide reporters are vulnerable to proteolytic sequestration themselves. Here we current a brand new method that permits the imaging of antigen proteolysis all through the processing pathway in an unbiased method. By incorporating bioorthogonal functionalities into the protein in place of methionines, antigens will be adopted throughout degradation, while leaving reactive sidechains open to templated and non-templated post-translational modifications, corresponding to citrullination and carbamylation.

Using this method, we adopted and imaged the post-uptake destiny of the generally used antigen ovalbumin, in addition to the post-translationally citrullinated and/or carbamylated auto-antigen vinculin in rheumatoid arthritis, revealing variations in antigen processing and presentation. Zika virus (ZIKV) has emerged as an vital world well being risk, with the not too long ago acquired capability to trigger extreme neurological signs and to persist inside host tissues.

We beforehand demonstrated that an early Asian lineage ZIKV isolate induces a extremely activated CD8 T cell response particular for an immunodominant epitope in the ZIKV envelope protein in wild-type mice. Here we present {that a} modern ZIKV isolate from the Brazilian outbreak severely limits CD8 T cell immunity in mice and blocks era of the immunodominant CD8 T cell response. This is related to a extra sustained an infection that’s cleared between 7- and 14-days post-infection.

HLA-B and cysteinylated ligands distinguish the antigen presentation landscape of extracellular vesicles

Mechanistically, we show that an infection with the Brazilian ZIKV isolate reduces the cross-presentation capability of dendritic cells and fails to completely activate the immunoproteasome. Thus, our examine supplies an isolate-specific mechanism of host immune evasion by one Brazilian ZIKV isolate, which differs from the early Asian lineage isolate and supplies potential perception into viral persistence related to current ZIKV outbreaks.

Immunostimulatory bacterial antigen-armed oncolytic measles virotherapy considerably will increase the efficiency of anti-PD1 checkpoint remedy

Clinical immunotherapy approaches are missing efficacy in the therapy of glioblastoma (GBM). In this examine, we sought to reverse native and systemic GBM-induced immunosuppression utilizing the Helicobacter pylori neutrophil-activating protein (NAP), a potent TLR2 agonist, as an immunostimulatory transgene expressed in an oncolytic measles virus (MV) platform, retargeted to permit viral entry by means of the urokinase-type plasminogen activator receptor (uPAR).

While single-agent murine anti-PD1 therapy or repeat in situ immunization with MV-s-NAP-uPA offered modest survival profit in MV-resistant syngeneic GBM fashions, the mixture therapy led to synergy with a remedy charge of 80% in mice bearing intracranial GL261 tumors and 72% in mice with CT-2A tumors.

Combination NAP-immunovirotherapy induced huge inflow of lymphoid cells in mouse mind, with CD8+ T cell predominance; therapeutic efficacy was CD8+ T cell dependent. Inhibition of the IFN response pathway utilizing the JAK1/JAK2 inhibitor ruxolitinib decreased PD-L1 expression on myeloid-derived suppressor cells in the mind and additional potentiated the therapeutic impact of MV-s-NAP-uPA and anti-PD1.

Our findings help the notion that MV strains armed with bacterial immunostimulatory antigens signify an efficient technique to beat the restricted efficacy of immune checkpoint inhibitor-based therapies in GBM, making a promising translational technique for this deadly mind tumor. One case was optimistic for HLA class I and HLA class II antibodies, whereas 9 circumstances have been optimistic for HLA class II antibodies, and the gene loci have been HLA-DR and/or DQ.

Antibody-mediated rejection (AMR) occurred in 4 of 10 sufferers in the DSA-positive group. Liver perform was irregular in 3 of 38 circumstances in the DSA-negative group. Multivariate evaluation revealed that DSA positivity was an impartial danger issue for liver insufficiency and long-term survival of recipients. In addition, Kaplan-Meier survival evaluation demonstrated that there have been vital variations in the survival of graft recipients between the DSA-positive group and the DSA-negative group (P<0.05).

E. coli antibody

20-ER13 Fitzgerald 1 ml 426 EUR
Description: Rabbit polyclonal E. coli antibody

E. coli antibody

10-E09C Fitzgerald 100 ug 159.6 EUR
Description: Mouse monoclonal E. coli antibody

E. coli antibody

10-E10A Fitzgerald 500 ug 591.6 EUR
Description: Mouse monoclonal E. coli antibody

E. coli antibody

10-E10B Fitzgerald 500 ug 591.6 EUR
Description: Mouse monoclonal E. coli antibody

E. coli antibody

20C-CR1244GP Fitzgerald 1 ml 561.6 EUR
Description: Goat polyclonal E. coli antibody

E. coli Antibody

abx022970-1ml Abbexa 1 ml 878.4 EUR

E. coli Antibody

abx022971-1ml Abbexa 1 ml 1161.6 EUR

E. coli Antibody

abx022975-1ml Abbexa 1 ml 718.8 EUR

E. coli Antibody

abx022977-1ml Abbexa 1 ml 811.2 EUR

E. coli Antibody

abx021669-1mg Abbexa 1 mg 1554 EUR

E. coli Antibody

abx021670-1mg Abbexa 1 mg 1045.2 EUR

E. coli Antibody

abx021671-02ml Abbexa 0.2 ml 594 EUR

E. coli Antibody

abx021672-1mg Abbexa 1 mg 1045.2 EUR

E. coli Antibody

abx021673-1mg Abbexa 1 mg 1045.2 EUR

Escherichia coli (E. coli) Antibody

abx415692-01mg Abbexa 0.1 mg 760.8 EUR

Escherichia coli (E. coli) Antibody

abx415712-1ml Abbexa 1 ml 727.2 EUR

Escherichia coli (E. coli) Antibody

abx411320-1ml Abbexa 1 ml 610.8 EUR

Rh Blood Group CcEe Antigens (RHCE) Antibody

20-abx211379 Abbexa
  • 493.20 EUR
  • 360.00 EUR
  • 100 ul
  • 50 ul

Rh Blood Group CcEe Antigens (RHCE) Antibody

abx413595-02mg Abbexa 0.2 mg 678 EUR

Rh Blood Group CcEe Antigens (RHCE) Antibody

abx413596-25ug Abbexa 25 ug 326.4 EUR

Rh Blood Group CcEe Antigens (RHCE) Antibody

20-abx339688 Abbexa
  • 493.20 EUR
  • 360.00 EUR
  • 100 ul
  • 50 ul

Recombiant (E. coli) Hepatitis C Virus (Hepatitis C Virus (HCV) Antigens-GST fusion protein (mosaic of several antigenic epitopes) (soluble)

HCV36-R Alpha Diagnostics each 343.2 EUR

Escherichia coli (E. coli) Antibody (FITC)

abx411322-1ml Abbexa 1 ml 610.8 EUR

Rabbit Anti-Mycoplasma pneumoniae IgG (all antigens)

MPPN12-A Alpha Diagnostics 100 ug 578.4 EUR

Escherichia coli (E. coli) Antibody (Biotin)

abx415713-1ml Abbexa 1 ml 861.6 EUR

Escherichia coli (E. coli) Antibody (Biotin)

abx411321-1ml Abbexa 1 ml 710.4 EUR

E. coli antibody (HRP)

60-E14 Fitzgerald 1 ml 489.6 EUR
Description: Rabbit polyclonal E. coli antibody (HRP) conjugated

E. coli Antibody (HRP)

abx022972-1ml Abbexa 1 ml 718.8 EUR

E. coli Antibody (HRP)

abx022978-1ml Abbexa 1 ml 1053.6 EUR

E. coli antibody (FITC)

60-E13 Fitzgerald 1 ml 453.6 EUR
Description: Rabbit polyclonal E. coli antibody (FITC) conjugated

E. coli Antibody (FITC)

abx022974-1ml Abbexa 1 ml 777.6 EUR

E. coli antibody (biotin)

60-E13B Fitzgerald 1 ml 561.6 EUR
Description: Rabbit polyclonal E. coli antibody (biotin) conjugated

E. coli Antibody (Biotin)

abx022976-1ml Abbexa 1 ml 718.8 EUR

E. coli Antibody (Biotin)

abx022979-1ml Abbexa 1 ml 886.8 EUR

Anti-Rat Tumor Antigens of Epithelial Origin antibody

STJ16100726 St John's Laboratory 100 µg 1164 EUR

Anti-Rat Tumour Antigens of Epithelial Origin antibody

STJ16100727 St John's Laboratory 100 µg 1164 EUR

E. Coli HCP antibody

20R-EG001 Fitzgerald 1 ml 1004.4 EUR
Description: Goat polyclonal E. Coli HCP antibody

E. coli Skp Antibody

32971-05111 AssayPro 150 ug 313.2 EUR

E. coli GOR Antibody

32540-05111 AssayPro 150 ug 313.2 EUR

E. coli NDK Antibody

32662-05111 AssayPro 150 ug 313.2 EUR

E. coli PPA Antibody

32678-05111 AssayPro 150 ug 313.2 EUR

E. coli glk Antibody

32864-05111 AssayPro 150 ug 313.2 EUR

E. coli O157 antibody

10-1490 Fitzgerald 100 ug 163.2 EUR
Description: Mouse monoclonal E. coli O157 antibody

E. coli O157 antibody

10-1521 Fitzgerald 100 ug 170.4 EUR
Description: Mouse monoclonal E. coli O157 antibody

E. coli O157 antibody

10C-CR1295M3 Fitzgerald 100 ug 470.4 EUR
Description: Mouse monoclonal E. coli O157 antibody

E. coli O157 antibody

10-E12A Fitzgerald 100 ug 462 EUR
Description: Mouse monoclonal E. coli O157 antibody

E. coli CysH Antibody

30281-05111 AssayPro 150 ug 313.2 EUR

E. coli DnaJ Antibody

32022-05111 AssayPro 150 ug 313.2 EUR

E. coli nanA Antibody

33092-05111 AssayPro 150 ug 313.2 EUR

E. Coli ldhA Antibody

32898-05111 AssayPro 150 ug 313.2 EUR

E. coli deoC Antibody

32936-05111 AssayPro 150 ug 313.2 EUR

E. coli pykF Antibody

32163-05111 AssayPro 150 ug 313.2 EUR

E. coli O157 Antibody

abx021684-1mg Abbexa 1 mg 1220.4 EUR

E. coli O157 Antibody

abx021685-1mg Abbexa 1 mg 1195.2 EUR

E. coli O157 Antibody

abx021686-1mg Abbexa 1 mg 1195.2 EUR

E. coli O157 Antibody

abx021687-1mg Abbexa 1 mg 1195.2 EUR

E. coli O157 Antibody

abx021688-1mg Abbexa 1 mg 1128 EUR

E. coli O157 Antibody

abx021689-1mg Abbexa 1 mg 1195.2 EUR

E. coli O157 Antibody

abx024017-1mg Abbexa 1 mg 1212 EUR

E. coli O157 Antibody

V3307-100UG NSJ Bioreagents 100 ug 349.3 EUR
Description: This mAb shows specificity to E. coli O157 in a simple ELISA. Escherichia coli are Gram negative bacterium that are commonly found in the lower intestine of warm-blooded organisms (endotherms). Their serological types are determined in combination with somatic antigens (O group: O1-O173) and flagella antigens (H type: H1-H56). The E. coli that cause intestinal infectious diseases including diarrhea, acute gastritis or colitis are referred to as pathogenic E. coli, which are classified into the following four groups according to differences in the mode of pathogenicity; enteropathogenic E. coli (EPEC), enteroinvasive E. coli (EIEC), enterotoxigenic E. coli (ETEC) and enterohemorrhagic E. coli (EHEC). Although the identification of pathogenic E. coli requires verification of their pathogenicity, pathogenic E. coli often have specific serotypes; therefore, typing of the serogroup and serotype is necessary in screening pathogenic E. coli.

E. coli O157 Antibody

V3307-20UG NSJ Bioreagents 20 ug 153.3 EUR
Description: This mAb shows specificity to E. coli O157 in a simple ELISA. Escherichia coli are Gram negative bacterium that are commonly found in the lower intestine of warm-blooded organisms (endotherms). Their serological types are determined in combination with somatic antigens (O group: O1-O173) and flagella antigens (H type: H1-H56). The E. coli that cause intestinal infectious diseases including diarrhea, acute gastritis or colitis are referred to as pathogenic E. coli, which are classified into the following four groups according to differences in the mode of pathogenicity; enteropathogenic E. coli (EPEC), enteroinvasive E. coli (EIEC), enterotoxigenic E. coli (ETEC) and enterohemorrhagic E. coli (EHEC). Although the identification of pathogenic E. coli requires verification of their pathogenicity, pathogenic E. coli often have specific serotypes; therefore, typing of the serogroup and serotype is necessary in screening pathogenic E. coli.

E. coli O157 Antibody

V3307SAF-100UG NSJ Bioreagents 100 ug 349.3 EUR
Description: This mAb shows specificity to E. coli O157 in a simple ELISA. Escherichia coli are Gram negative bacterium that are commonly found in the lower intestine of warm-blooded organisms (endotherms). Their serological types are determined in combination with somatic antigens (O group: O1-O173) and flagella antigens (H type: H1-H56). The E. coli that cause intestinal infectious diseases including diarrhea, acute gastritis or colitis are referred to as pathogenic E. coli, which are classified into the following four groups according to differences in the mode of pathogenicity; enteropathogenic E. coli (EPEC), enteroinvasive E. coli (EIEC), enterotoxigenic E. coli (ETEC) and enterohemorrhagic E. coli (EHEC). Although the identification of pathogenic E. coli requires verification of their pathogenicity, pathogenic E. coli often have specific serotypes; therefore, typing of the serogroup and serotype is necessary in screening pathogenic E. coli.

Inactivated DENV-2 Antigen (E. coli)

VAng-Lsx0084-1mg Creative Biolabs 1 mg 986.4 EUR
Description: DENV-2, natural antigen from E. coli.

E. coli GroEL Antibody

20012-05011 AssayPro 150 ug 260.4 EUR

E. coli antibody (K99 Pilus)

10-E20A Fitzgerald 500 ug 591.6 EUR
Description: Mouse monoclonal E. coli antibody (K99 Pilus)

Hepatitis A Virus (HAV) Antigens

HAV17-N-10 Alpha Diagnostics 10 ug Ask for price

HLA-DR Antigens-Associated Invariant Chain (HLA-DR) Antibody

abx140231-01mg Abbexa 0.1 mg 444 EUR

HLA-DR Antigens-Associated Invariant Chain (HLA-DR) Antibody

abx140253-01mg Abbexa 0.1 mg 444 EUR

HLA-DR Antigens-Associated Invariant Chain (HLA-DR) Antibody

abx140254-01mg Abbexa 0.1 mg 444 EUR

HLA-DR Antigens-Associated Invariant Chain (HLA-DR) Antibody

abx140257-01mg Abbexa 0.1 mg 444 EUR

HLA-DR Antigens-Associated Invariant Chain (HLA-DR) Antibody

abx415437-025mg Abbexa 0.25 mg 678 EUR

HLA-DR Antigens-Associated Invariant Chain (HLA-DR) Antibody

abx415449-02mg Abbexa 0.2 mg 678 EUR

HLA-DR Antigens-Associated Invariant Chain (HLA-DR) Antibody

abx413474-02mg Abbexa 0.2 mg 678 EUR

HLA-DR Antigens-Associated Invariant Chain (HLA-DR) Antibody

abx200524-100ug Abbexa 100 ug 393.6 EUR

Rabbit Anti-E. coli all ag's Polyclonal Antibody

DPAB0123 Creative Diagnostics 1 ml 999.6 EUR

Rabbit Anti-E. coli all ag's Polyclonal Antibody

DPAB0126 Creative Diagnostics 1 ml 1146 EUR

Escherichia coli Serotype O2 (E. coli O2) Antibody

abx411330-02mg Abbexa 0.2 mg 678 EUR

E. coli O157:H7 antibody

70-XG13 Fitzgerald 1 mg 734.4 EUR
Description: Affinity purified Goat polyclonal E. coli O157:H7 antibody. 

E. coli O157 (9.88) Antibody

BNC470207-100 Biotium 100uL 238.8 EUR
Description: Primary antibody against E. coli O157 (9.88),CF647 conjugate, Concentration: 0.1mg/mL

E. coli O157 (9.88) Antibody

BNC470207-500 Biotium 500uL 652.8 EUR
Description: Primary antibody against E. coli O157 (9.88),CF647 conjugate, Concentration: 0.1mg/mL

E. coli O157 (9.88) Antibody

BNC550207-100 Biotium 100uL 238.8 EUR
Description: Primary antibody against E. coli O157 (9.88),CF555 conjugate, Concentration: 0.1mg/mL

E. coli O157 (9.88) Antibody

BNC550207-500 Biotium 500uL 652.8 EUR
Description: Primary antibody against E. coli O157 (9.88),CF555 conjugate, Concentration: 0.1mg/mL

E. coli O157 (9.88) Antibody

BNC400207-100 Biotium 100uL 238.8 EUR
Description: Primary antibody against E. coli O157 (9.88),CF640R conjugate, Concentration: 0.1mg/mL

E. coli O157 (9.88) Antibody

BNC400207-500 Biotium 500uL 652.8 EUR
Description: Primary antibody against E. coli O157 (9.88),CF640R conjugate, Concentration: 0.1mg/mL

E. coli O157 (9.88) Antibody

BNC430207-100 Biotium 100uL 238.8 EUR
Description: Primary antibody against E. coli O157 (9.88),CF543 conjugate, Concentration: 0.1mg/mL

E. coli O157 (9.88) Antibody

BNC430207-500 Biotium 500uL 652.8 EUR
Description: Primary antibody against E. coli O157 (9.88),CF543 conjugate, Concentration: 0.1mg/mL

E. coli O157 (9.88) Antibody

BNC810207-100 Biotium 100uL 238.8 EUR
Description: Primary antibody against E. coli O157 (9.88),CF680R conjugate, Concentration: 0.1mg/mL

E. coli O157 (9.88) Antibody

BNC810207-500 Biotium 500uL 652.8 EUR
Description: Primary antibody against E. coli O157 (9.88),CF680R conjugate, Concentration: 0.1mg/mL

E. coli O157 (9.88) Antibody

BNC610207-100 Biotium 100uL 238.8 EUR
Description: Primary antibody against E. coli O157 (9.88),CF660R conjugate, Concentration: 0.1mg/mL

E. coli O157 (9.88) Antibody

BNC610207-500 Biotium 500uL 652.8 EUR
Description: Primary antibody against E. coli O157 (9.88),CF660R conjugate, Concentration: 0.1mg/mL

E. coli O157 (9.88) Antibody

BNUM0207-50 Biotium 50uL 474 EUR
Description: Primary antibody against E. coli O157 (9.88), 1mg/mL

E. coli O157 (9.88) Antibody

BNCB0207-100 Biotium 100uL 238.8 EUR
Description: Primary antibody against E. coli O157 (9.88),Biotin conjugate, Concentration: 0.1mg/mL

E. coli O157 (9.88) Antibody

BNCB0207-500 Biotium 500uL 652.8 EUR
Description: Primary antibody against E. coli O157 (9.88),Biotin conjugate, Concentration: 0.1mg/mL

E. coli O157 (9.88) Antibody

BNCP0207-250 Biotium 250uL 459.6 EUR
Description: Primary antibody against E. coli O157 (9.88),PerCP conjugate, Concentration: 0.1mg/mL

E. coli O157 (9.88) Antibody

BNCA0207-250 Biotium 250uL 459.6 EUR
Description: Primary antibody against E. coli O157 (9.88),APC conjugate, Concentration: 0.1mg/mL

E. coli O157 (9.88) Antibody

BNCAP0207-100 Biotium 100uL 238.8 EUR
Description: Primary antibody against E. coli O157 (9.88),Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

E. coli O157 (9.88) Antibody

BNCAP0207-500 Biotium 500uL 652.8 EUR
Description: Primary antibody against E. coli O157 (9.88),Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

E. coli O157 (9.88) Antibody

BNC940207-100 Biotium 100uL 238.8 EUR
Description: Primary antibody against E. coli O157 (9.88),CF594 conjugate, Concentration: 0.1mg/mL

E. coli O157 (9.88) Antibody

BNC940207-500 Biotium 500uL 652.8 EUR
Description: Primary antibody against E. coli O157 (9.88),CF594 conjugate, Concentration: 0.1mg/mL

E. coli O157 (9.88) Antibody

BNCH0207-100 Biotium 100uL 238.8 EUR
Description: Primary antibody against E. coli O157 (9.88),Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

E. coli O157 (9.88) Antibody

BNCH0207-500 Biotium 500uL 652.8 EUR
Description: Primary antibody against E. coli O157 (9.88),Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

E. coli O157 (9.88) Antibody

BNUB0207-100 Biotium 100uL 250.8 EUR
Description: Primary antibody against E. coli O157 (9.88), Concentration: 0.2mg/mL

E. coli O157 (9.88) Antibody

BNUB0207-500 Biotium 500uL 549.6 EUR
Description: Primary antibody against E. coli O157 (9.88), Concentration: 0.2mg/mL

E. coli O157:H7 Antibody

abx022980-1mg Abbexa 1 mg 718.8 EUR

E. coli O157 (9.88) Antibody

BNC040207-100 Biotium 100uL 238.8 EUR
Description: Primary antibody against E. coli O157 (9.88),CF405S conjugate, Concentration: 0.1mg/mL

E. coli O157 (9.88) Antibody

BNC040207-500 Biotium 500uL 652.8 EUR
Description: Primary antibody against E. coli O157 (9.88),CF405S conjugate, Concentration: 0.1mg/mL

E. coli O157 (9.88) Antibody

BNC050207-100 Biotium 100uL 238.8 EUR
Description: Primary antibody against E. coli O157 (9.88),CF405M conjugate, Concentration: 0.1mg/mL

E. coli O157 (9.88) Antibody

BNC050207-500 Biotium 500uL 652.8 EUR
Description: Primary antibody against E. coli O157 (9.88),CF405M conjugate, Concentration: 0.1mg/mL

E. coli O157 (9.88) Antibody

BNC700207-100 Biotium 100uL 238.8 EUR
Description: Primary antibody against E. coli O157 (9.88),CF770 conjugate, Concentration: 0.1mg/mL

E. coli O157 (9.88) Antibody

BNC700207-500 Biotium 500uL 652.8 EUR
Description: Primary antibody against E. coli O157 (9.88),CF770 conjugate, Concentration: 0.1mg/mL

E. coli O157 (9.88) Antibody

BNC800207-100 Biotium 100uL 238.8 EUR
Description: Primary antibody against E. coli O157 (9.88),CF680 conjugate, Concentration: 0.1mg/mL

E. coli O157 (9.88) Antibody

BNC800207-500 Biotium 500uL 652.8 EUR
Description: Primary antibody against E. coli O157 (9.88),CF680 conjugate, Concentration: 0.1mg/mL

E. coli O157 (9.88) Antibody

BNC680207-100 Biotium 100uL 238.8 EUR
Description: Primary antibody against E. coli O157 (9.88),CF568 conjugate, Concentration: 0.1mg/mL

E. coli O157 (9.88) Antibody

BNC680207-500 Biotium 500uL 652.8 EUR
Description: Primary antibody against E. coli O157 (9.88),CF568 conjugate, Concentration: 0.1mg/mL

E. coli O157 (9.88) Antibody

BNC880207-100 Biotium 100uL 238.8 EUR
Description: Primary antibody against E. coli O157 (9.88),CF488A conjugate, Concentration: 0.1mg/mL

E. coli O157 (9.88) Antibody

BNC880207-500 Biotium 500uL 652.8 EUR
Description: Primary antibody against E. coli O157 (9.88),CF488A conjugate, Concentration: 0.1mg/mL

E. coli O157 (9.88) Antibody

BNCR0207-250 Biotium 250uL 459.6 EUR
Description: Primary antibody against E. coli O157 (9.88),RPE conjugate, Concentration: 0.1mg/mL

E. coli O157 antibody (FITC)

61C-CR1295M1F Fitzgerald 100 ug 489.6 EUR
Description: Mouse monoclonal E. coli O157 antibody (FITC)

E. coli O157 antibody (FITC)

61C-CR1295M4F Fitzgerald 100 ug 561.6 EUR
Description: Mouse monoclonal E. coli O157 antibody (FITC)

Mouse antibody for E. coli

1063 Virostat 100 ug 438.46 EUR
Description: This is Mouse monoclonal FITC conjugated antibody against E coli O157 for WB, ELISA.

E. coli O157 Antibody (FITC)

abx021683-1mg Abbexa 1 mg 2798.4 EUR

HLA-DR Antigens-Associated Invariant Chain (HLA-DR) Antibody (PE)

abx140294-100tests Abbexa 100 tests 577.2 EUR

HLA-DR Antigens-Associated Invariant Chain (HLA-DR) Antibody (PE)

abx140305-100tests Abbexa 100 tests 577.2 EUR

HLA-DR Antigens-Associated Invariant Chain (HLA-DR) Antibody (PE)

abx200526-100tests Abbexa 100 tests 543.6 EUR

HLA-DR Antigens-Associated Invariant Chain (HLA-DR) Antibody (APC)

abx140295-100tests Abbexa 100 tests 577.2 EUR

HLA-DR Antigens-Associated Invariant Chain (HLA-DR) Antibody (APC)

abx140306-100tests Abbexa 100 tests 577.2 EUR

HLA-DR Antigens-Associated Invariant Chain (HLA-DR) Antibody (RPE)

abx415436-100tests Abbexa 100 tests 710.4 EUR

HLA-DR Antigens-Associated Invariant Chain (HLA-DR) Antibody (RPE)

abx413475-100tests Abbexa 100 tests 710.4 EUR

HLA-DR Antigens-Associated Invariant Chain (HLA-DR) Antibody (APC)

abx200527-100tests Abbexa 100 tests 760.8 EUR

E. coli 0157:H7 antibody (HRP)

60-E07 Fitzgerald 100 ug 619.2 EUR
Description: Goat polyclonal E. coli 0157:H7 antibody (HRP) conjugated

HLA-DR Antigens-Associated Invariant Chain (HLA-DR) Antibody (PerCP)

abx140293-100tests Abbexa 100 tests 577.2 EUR

HLA-DR Antigens-Associated Invariant Chain (HLA-DR) Antibody (FITC)

abx415435-01mg Abbexa 0.1 mg 610.8 EUR

HLA-DR Antigens-Associated Invariant Chain (HLA-DR) Antibody (PerCP)

abx200528-100tests Abbexa 100 tests 543.6 EUR

Escherichia coli Serotype O15 (E. coli O15) Antibody

abx411331-02mg Abbexa 0.2 mg 678 EUR

Escherichia coli Serotype O20 (E. coli O20) Antibody

abx411332-02mg Abbexa 0.2 mg 678 EUR

E. coli 0157:H7 antibody (FITC)

60-E08 Fitzgerald 500 ug 676.8 EUR
Description: Goat polyclonal E. coli 0157:H7 antibody (FITC) conjugated

E. coli Enterotoxin LT Antibody

abx023834-1mg Abbexa 1 mg 878.4 EUR

E. coli Enterotoxin LT Antibody

abx023835-1mg Abbexa 1 mg 878.4 EUR

E. coli Enterotoxin LT Antibody

abx023836-1mg Abbexa 1 mg 878.4 EUR

E. coli Enterotoxin LT Antibody

abx023837-1mg Abbexa 1 mg 878.4 EUR

E. coli Enterotoxin B Antibody

abx021678-1mg Abbexa 1 mg 718.8 EUR

E. coli Enterotoxin B Antibody

abx021679-1mg Abbexa 1 mg 727.2 EUR

E. coli Enterotoxin B Antibody

abx021680-1mg Abbexa 1 mg 718.8 EUR

E. coli Glycerol Kinase Antibody

32699-05111 AssayPro 150 ug 313.2 EUR

E. coli Enterotoxin STp Antibody

abx023838-1mg Abbexa 1 mg 1053.6 EUR

E. coli Enterotoxin STp Antibody

abx023839-1mg Abbexa 1 mg 1053.6 EUR

E. coli Enterotoxin STp Antibody

abx023840-1mg Abbexa 1 mg 1053.6 EUR

E. coli Tryptophanase (Tnase) Antibody

33517-05111 AssayPro 150 ug 313.2 EUR

Escherichia coli 987P Pili (E. coli 987P Pilus) Antibody

abx411323-1ml Abbexa 1 ml 610.8 EUR

Rabbit Anti-Borrelia burgdorferi (whole antigens) IgG

BBA12-A Alpha Diagnostics 100 ul 562.8 EUR
×

The positivity of DSAs after pediatric liver transplantation was intently associated to the incidence of AMR. These outcomes prompt that DSAs needs to be routinely monitored post-operatively, and that DSA-positive recipients needs to be screened as quickly as attainable and given acceptable therapy.

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Recent Posts

  • Compare antibodies lab reagents for research
  • AGL1 Electrocompetent Agrobacterium
  • EUA Authorized Serology Test Performance
  • Evaluation of a rapid antigen test to detect SARS-CoV-2 infection and identify potentially infectious individuals
  • Anti-cancer immunoprotective effects of immunization with hydatid cyst wall antigens in a non-immunogenic and metastatic triple-negative murine mammary carcinoma model
  • A bacterial assay for rapid screening of IAA catabolic enzymes.
  • Data on isolation and purification of fibrinolytic enzyme from Pseudomonas baetica SUHU25.
  • E coli
  • EIA
  • electrophoresis
  • Isolation, Purification, and Characterization of Ginger-derived Nanoparticles (GDNPs) from Ginger, Rhizome of Zingiber officinale
  • Low pH Exposure During Immunoglobulin G Purification Methods Results in Aggregates That Avidly Bind Fcγ Receptors: Implications for Measuring Fc Dependent Antibody Functions.
  • Percp
  • peroxidase
  • plex
  • precipitation
  • Premix
  • Preps
  • primers
  • probe
  • Production of a polyclonal antibody against acrylamide for immunochromatographic detection of acrylamide using strip tests.
  • profile
  • profiling
  • Pure
  • Purification
  • purified
  • Rabbit
  • Real-time
  • Removal of Endotoxin from rAAV Samples Using a Simple Detergent-Based Protocol.
  • Rhesus

biology cells notes biology cells parts biology cells pdf biology cells practice test biology cells questions biology cells quiz cannabis assay kits cdna 260/280 cia kids cia kids camp cia kids classes cia kids code cia kids cooking cia kids games creatinine assay kits enzymes for gluten enzymes for heart mineral assay kits msd assay kits panela panela cheese paneles solares paneling paneling for walls panelist panella panelling panelpolls panels4less panel siding panel tactil paneltronics panel truck panel van particles and atoms peptidescience.com peptidesciences peptides t3 peptides tadalafil peptides vs hgh peptides warehouse peptides warehouse scam reagents coa reagents define reagents defined

Archives

  • December 2022
  • June 2022
  • December 2021
  • September 2021
  • August 2021
  • July 2021
  • January 2021
  • May 2020
  • March 2020

Categories

  • A bacterial assay for rapid screening of IAA catabolic enzymes.
  • Data on isolation and purification of fibrinolytic enzyme from Pseudomonas baetica SUHU25.
  • E coli
  • EIA
  • electrophoresis
  • Isolation, Purification, and Characterization of Ginger-derived Nanoparticles (GDNPs) from Ginger, Rhizome of Zingiber officinale
  • Low pH Exposure During Immunoglobulin G Purification Methods Results in Aggregates That Avidly Bind Fcγ Receptors: Implications for Measuring Fc Dependent Antibody Functions.
  • Percp
  • peroxidase
  • plex
  • precipitation
  • Premix
  • Preps
  • primers
  • probe
  • Production of a polyclonal antibody against acrylamide for immunochromatographic detection of acrylamide using strip tests.
  • profile
  • profiling
  • Pure
  • Purification
  • purified
  • Rabbit
  • Real-time
  • Removal of Endotoxin from rAAV Samples Using a Simple Detergent-Based Protocol.
  • Rhesus

Meta

  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org
  • A bacterial assay for rapid screening of IAA catabolic enzymes.
  • Data on isolation and purification of fibrinolytic enzyme from Pseudomonas baetica SUHU25.
  • E coli
  • EIA
  • electrophoresis
  • Isolation, Purification, and Characterization of Ginger-derived Nanoparticles (GDNPs) from Ginger, Rhizome of Zingiber officinale
  • Low pH Exposure During Immunoglobulin G Purification Methods Results in Aggregates That Avidly Bind Fcγ Receptors: Implications for Measuring Fc Dependent Antibody Functions.
  • Percp
  • peroxidase
  • plex
  • precipitation
  • Premix
  • Preps
  • primers
  • probe
  • Production of a polyclonal antibody against acrylamide for immunochromatographic detection of acrylamide using strip tests.
  • profile
  • profiling
  • Pure
  • Purification
  • purified
  • Rabbit
  • Real-time
  • Removal of Endotoxin from rAAV Samples Using a Simple Detergent-Based Protocol.
  • Rhesus
  • Compare antibodies lab reagents for research
  • AGL1 Electrocompetent Agrobacterium
  • EUA Authorized Serology Test Performance
  • Evaluation of a rapid antigen test to detect SARS-CoV-2 infection and identify potentially infectious individuals
  • Anti-cancer immunoprotective effects of immunization with hydatid cyst wall antigens in a non-immunogenic and metastatic triple-negative murine mammary carcinoma model

biology cells notes biology cells parts biology cells pdf biology cells practice test biology cells questions biology cells quiz cannabis assay kits cdna 260/280 cia kids cia kids camp cia kids classes cia kids code cia kids cooking cia kids games creatinine assay kits enzymes for gluten enzymes for heart mineral assay kits msd assay kits panela panela cheese paneles solares paneling paneling for walls panelist panella panelling panelpolls panels4less panel siding panel tactil paneltronics panel truck panel van particles and atoms peptidescience.com peptidesciences peptides t3 peptides tadalafil peptides vs hgh peptides warehouse peptides warehouse scam reagents coa reagents define reagents defined

© 2023 Signet Laboratories | Powered by Superbs Personal Blog theme